The Menopause Rating Scale — Tracking Symptoms Beyond "Hot Flashes Bad"
Menopause is one of the most undertreated areas in women's health software. Most period trackers stop at perimenopause ("you're tracking irregular cycles, here's a chart"), nothing surfaces the bigger symptom picture, and the women's-health conversation skips ahead to pregnancy as if menopause weren't an entire decade-plus chapter for the same body. The clinical world has known this for years and quietly settled on a standard tool: the Menopause Rating Scale (MRS).
What the MRS is
Developed by Heinemann and colleagues in 1996, validated worldwide across cultures, used in clinical trials and primary care alike. 11 symptoms, each scored 0 (none) to 4 (very severe). Total range 0–44. The 11 items group into three clinically distinct subscales:
Somato-vegetative (4 items) — hot flashes / sweating, heart discomfort, sleep problems, joint and muscular discomfort
Psychological (4 items) — depressive mood, irritability, anxiety, physical and mental exhaustion
Urogenital (3 items) — sexual problems, bladder problems, vaginal dryness
The total score gives you a single severity bucket (none / mild / moderate / severe). The subscale scores tell you where the burden lies.
Why the subscales matter more than the total
This is the part that genuinely matters clinically. Different subscales respond to different treatments, and the right treatment depends on which symptoms are actually disrupting your life.
Vasomotor symptoms (hot flashes, night sweats — captured in the somato-vegetative subscale) are what menopausal hormone therapy (MHT, what used to be called HRT) is most effective for. If your subscale-1 score is high, that's the conversation that matters. Several non-hormonal options also help here: low-dose paroxetine, gabapentin, oxybutynin, and the newer NK3 receptor antagonists.
Psychological symptoms can be hormonal, but they can also be the rest of life happening at the same age. Empty nest, aging parents, career inflection points, sleep disruption (which is often somato-vegetative driven). The subscale-2 score doesn't tell you which is which — but a clinician can untangle it once they see the breakdown.
Urogenital symptoms are the ones most often dismissed and most undertreated. Vaginal dryness, painful intercourse, bladder urgency — all respond extremely well to low-dose local estrogen (cream, ring, or tablet), which is safe even for many women who can't take systemic hormone therapy. Yet vast numbers of women aren't told this option exists. A high subscale-3 score is the entry to that conversation.
A high total score doesn't tell your provider any of this. The breakdown does.
The severity buckets
For the total: - 0–4: no / minimal complaints - 5–8: mild - 9–15: moderate - 16+: severe
But the actionable conversation is per-subscale. A score of 14 driven entirely by somato-vegetative symptoms is a different visit than a 14 driven entirely by urogenital ones.
Why repeating the MRS matters
A single MRS snapshot is informative; a series across months is much more so. Symptoms during menopause aren't stable — they shift, evolve, and respond (or don't) to whatever's tried. Bringing 4 MRS scores from across 6 months to a follow-up visit lets your provider see whether something is working, whether new symptoms are emerging, and whether the burden is shifting between subscales.
This is genuinely useful clinical information that providers usually have to construct on the fly from "how have things been since last time, in general?" The structured score saves a lot of memory work.
What the MRS doesn't do
It doesn't diagnose menopause (that's by clinical history — 12 months without a period). It doesn't tell you whether to start MHT (that's a risk-benefit conversation that depends on your age, time since menopause, family history, and what specifically is bothering you). It doesn't replace lab work in atypical cases (FSH, estradiol, thyroid panel — when the symptom picture is unclear).
It does give you and your provider a shared, validated language for "how bad is this and what's bothering you most." Which, in 15-minute visits, is everything.
The skipped conversation
The Women's Health Initiative trial in 2002 dramatically reduced HRT use after raising concerns about cardiovascular and breast cancer risk. Subsequent re-analysis has substantially nuanced those findings — for younger menopausal women (under 60, within 10 years of menopause) the risk-benefit profile of MHT is much more favorable than the headline takeaway from 2002 suggested. Many women who could benefit from MHT have spent the last two decades being told to white-knuckle through it. The conversation is worth re-opening with a current provider, especially if vasomotor symptoms are dominant.
Skip the paper form
The Menopause Symptom Score tool gives you the MRS with auto-scoring and the three subscale breakouts. History saving is opt-in (off by default) — when on, you can compare scores across months to spot trends. Same on-device privacy as the rest of /health — localStorage only, no upload, no account.
The short version
11 items, 3 subscales, total 0–44. The subscale scores matter more than the total because different mechanisms drive each, and different treatments help. Repeat it across months for the trend. Bring it to your provider — the structured score saves the time you'd otherwise spend reconstructing how things have been. And if vasomotor symptoms dominate and you've never had the MHT conversation in the last few years, it's worth raising again.